Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ferry

Showing results (121-130 of 125) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 125 results.
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
Journal of the American College of Cardiology|February 14, 1998
Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research InvestigatorsD R Ferry, R A O'Rourke, A S Blaustein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal CancerRussell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.
Lancet (London, England)|October 8, 2013
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialCharles S Fuchs, Jiri Tomasek, Cho Jae Yong, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|March 13, 2019
Clinical management practices of life-threatening asthma: an audit of practices in intensive carePaul Secombe, Penny Stewart, Sunil Singh, et al.
Pageof 13

Showing results (121-130 of 125) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 125 results.
The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.
Journal of the American College of Cardiology|February 14, 1998
Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. VANQWISH Trial Research InvestigatorsD R Ferry, R A O'Rourke, A S Blaustein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2017
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal CancerRussell D Petty, Asa Dahle-Smith, David A J Stevenson, et al.
Lancet (London, England)|October 8, 2013
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialCharles S Fuchs, Jiri Tomasek, Cho Jae Yong, et al.
Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine|March 13, 2019
Clinical management practices of life-threatening asthma: an audit of practices in intensive carePaul Secombe, Penny Stewart, Sunil Singh, et al.
Pageof 13